Physiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive children

PAGE 30 (2022) Abstr 10101
Eriksson J, Sjögren E, Pellowe M, Choy RKM, Mistilis J, Jarrahian C, Zehrung D, Vora LK, Volpe-Zanutto F, Tekko IA, Donnelly RF, Chenel M.
ConferenceInfectious diseasesPBPK/PBBM

Pharmetheus Affiliates

Portrait-of-Johanna-Eriksson_Pharmetheus
Senior Director, MIDD Consultant

Johanna Eriksson

See bio
Portrait-of-Erik-Sjogren_Pharmetheus-2
Principal Director, PBPK & PBBM Scientific Lead

Erik Sjögren

See bio
Portrait-of-Moriah-Pellowe_Pharmetheus
Director, MIDD Consultant

Moriah Pellowe

See bio
Portrait-of-Marylore-Chenel_Pharmetheus
Chief Research Officer

Marylore Chenel

See bio